Sinopharm Tech Holdings Limited provides unaudited consolidated earnings guidance for the three months ended 30 September 2022. For the period, the company expects profit attributable to equity holders of the Company of not less than HKD 4.0 million as compared with a loss attributable to equity holders of the Company of approximately HKD 9.4 million for the corresponding period in 2021.